NUWE vs MMSI vs NVCR vs ANGO vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -5. 4% for Nuwellis, Inc. (NUWE). Boston Scientific Corporation (BSX) offers the better valuation at 29. 2x trailing P/E (16. 0x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Boston Scientific Corporation (BSX) is the cheapest at 29.

2x versus Merit Medical Systems, Inc. at 29. 3x. On forward P/E, Merit Medical Systems, Inc. is actually cheaper at 15. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -100. 0% for Nuwellis, Inc. (NUWE). Over 10 years, the gap is even starker: MMSI returned +209. 3% versus NUWE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

30β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 616% more volatile than BSX relative to the S&P 500. On balance sheet safety, Nuwellis, Inc. (NUWE) carries a lower debt/equity ratio of 13% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -5. 4% for Nuwellis, Inc. (NUWE). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -217. 4% for Nuwellis, Inc.. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -211. 8% for Nuwellis, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -134. 3% for NUWE. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Merit Medical Systems, Inc.

(MMSI) trades at 15. 1x forward P/E versus 16. 0x for Boston Scientific Corporation — 0. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

30), +143. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BSX: +143. 6%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NUWE is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ANGO is a small-cap quality compounder stock; BSX is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.